Insider sales of Brink's shares at a price below the current rate is seen as a negative sign, suggesting insiders believe the shares are fully valued. The absence of insider purchases over the past year and their lack of significant ownership in the company warrant caution before buying shares.
Insider share sales, particularly below current price, are often seen as negative, implying a lower price is reasonable. Reasons for selling can vary. Modest insider ownership suggests alignment with the company. Lack of recent insider transactions is not encouraging.
Despite a drop in EPS, the market is gauging progress with other metrics. The modest 1.1% dividend yield may not significantly support the share price. The company's strong share price momentum indicates positive sentiment.
Despite Brink's limited recent growth, investors hope for a business turnaround. The high P/E ratio, inconsistent earnings growth, and forecasted below-market growth suggests the share price could drop.
Insider selling at Brink's may suggest low faith in the company's valuation. Lack of insider buying and moderate ownership levels show a lack of alignment between management and smaller shareholders, suggesting caution for potential investors.
I'm up 33% this year. I do not dabble in options. I don't understand them well enough to always make money. So, instead I buy and hold for up to 6 months, maybe a year depending on the stock itself. Some things I hold onto because of the dividends like$奧馳亞(MO.US)$&$艾伯維公司(ABBV.US)$. But I also hold positions in$百勝中國(YUMC.US)$(+29%);$Pinterest(PINS.US)$(+16%);$Dropbox(DBX.US)$(+9.5%); and$The Brink's(BCO.US)$. For$The Brink's(BCO.US)$I've owned this since last July and am up 60% - about to dump that one before the end of the year.
A couple of days left here ahead of the 4th of July weekend. The casino is closed on Monday, institutional sweeping activity was bullish on Wednesday and has been the whole week so far. Biotechs were in focus on Wednesday but other than that, there was no real sector focus that stood out. Institutional sweepers were selectively active in few tech names, some underbelly growth names, energy and even in a few re-opening plays. On the sentiment front Intraday sentiment finished the session around neutral.Neutral sentiment plus an elevated gamma have created a backdrop for a sloppy push higher in the major indices but aggressive rotation continues to play a major role. Rotation into tech and growth names having already done a lot of damage, names like ...
The Brink's股票討論區
專欄Options Montage: Either a rotation or a breather
Biotechs were in focus on Wednesday but other than that, there was no real sector focus that stood out. Institutional sweepers were selectively active in few tech names, some underbelly growth names, energy and even in a few re-opening plays.
On the sentiment front
Intraday sentiment finished the session around neutral.Neutral sentiment plus an elevated gamma have created a backdrop for a sloppy push higher in the major indices but aggressive rotation continues to play a major role.
Rotation into tech and growth names having already done a lot of damage, names like ...
暫無評論